342 related articles for article (PubMed ID: 36698417)
1. Artificial intelligence applied in neoantigen identification facilitates personalized cancer immunotherapy.
Cai Y; Chen R; Gao S; Li W; Liu Y; Su G; Song M; Jiang M; Jiang C; Zhang X
Front Oncol; 2022; 12():1054231. PubMed ID: 36698417
[TBL] [Abstract][Full Text] [Related]
2. Challenges targeting cancer neoantigens in 2021: a systematic literature review.
Chen I; Chen MY; Goedegebuure SP; Gillanders WE
Expert Rev Vaccines; 2021 Jul; 20(7):827-837. PubMed ID: 34047245
[No Abstract] [Full Text] [Related]
3. Cancer Neoantigens: Challenges and Future Directions for Prediction, Prioritization, and Validation.
Borden ES; Buetow KH; Wilson MA; Hastings KT
Front Oncol; 2022; 12():836821. PubMed ID: 35311072
[TBL] [Abstract][Full Text] [Related]
4. Neoantigen identification: Technological advances and challenges.
Pu T; Peddle A; Zhu J; Tejpar S; Verbandt S
Methods Cell Biol; 2024; 183():265-302. PubMed ID: 38548414
[TBL] [Abstract][Full Text] [Related]
5. Immune-based mutation classification enables neoantigen prioritization and immune feature discovery in cancer immunotherapy.
Bai P; Li Y; Zhou Q; Xia J; Wei PC; Deng H; Wu M; Chan SK; Kappler JW; Zhou Y; Tran E; Marrack P; Yin L
Oncoimmunology; 2021 Jan; 10(1):1868130. PubMed ID: 33537173
[TBL] [Abstract][Full Text] [Related]
6. Application of mass spectrometry-based MHC immunopeptidome profiling in neoantigen identification for tumor immunotherapy.
Zhang X; Qi Y; Zhang Q; Liu W
Biomed Pharmacother; 2019 Dec; 120():109542. PubMed ID: 31629254
[TBL] [Abstract][Full Text] [Related]
7. Artificial intelligence and neoantigens: paving the path for precision cancer immunotherapy.
Bulashevska A; Nacsa Z; Lang F; Braun M; Machyna M; Diken M; Childs L; König R
Front Immunol; 2024; 15():1394003. PubMed ID: 38868767
[TBL] [Abstract][Full Text] [Related]
8. Neodb: a comprehensive neoantigen database and discovery platform for cancer immunotherapy.
Wu T; Chen J; Diao K; Wang G; Wang J; Yao H; Liu XS
Database (Oxford); 2023 Jun; 2023():. PubMed ID: 37311149
[TBL] [Abstract][Full Text] [Related]
9. Neopepsee: accurate genome-level prediction of neoantigens by harnessing sequence and amino acid immunogenicity information.
Kim S; Kim HS; Kim E; Lee MG; Shin EC; Paik S; Kim S
Ann Oncol; 2018 Apr; 29(4):1030-1036. PubMed ID: 29360924
[TBL] [Abstract][Full Text] [Related]
10. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors.
Chen F; Zou Z; Du J; Su S; Shao J; Meng F; Yang J; Xu Q; Ding N; Yang Y; Liu Q; Wang Q; Sun Z; Zhou S; Du S; Wei J; Liu B
J Clin Invest; 2019 May; 129(5):2056-2070. PubMed ID: 30835255
[TBL] [Abstract][Full Text] [Related]
11. ProGeo-neo: a customized proteogenomic workflow for neoantigen prediction and selection.
Li Y; Wang G; Tan X; Ouyang J; Zhang M; Song X; Liu Q; Leng Q; Chen L; Xie L
BMC Med Genomics; 2020 Apr; 13(Suppl 5):52. PubMed ID: 32241270
[TBL] [Abstract][Full Text] [Related]
12. Improvement in neoantigen prediction via integration of RNA sequencing data for variant calling.
Nguyen BQT; Tran TPD; Nguyen HT; Nguyen TN; Pham TMQ; Nguyen HTP; Tran DH; Nguyen V; Tran TS; Pham TN; Le MT; Phan MD; Giang H; Nguyen HN; Tran LS
Front Immunol; 2023; 14():1251603. PubMed ID: 37731488
[TBL] [Abstract][Full Text] [Related]
13. Machine learning methods and harmonized datasets improve immunogenic neoantigen prediction.
Müller M; Huber F; Arnaud M; Kraemer AI; Altimiras ER; Michaux J; Taillandier-Coindard M; Chiffelle J; Murgues B; Gehret T; Auger A; Stevenson BJ; Coukos G; Harari A; Bassani-Sternberg M
Immunity; 2023 Nov; 56(11):2650-2663.e6. PubMed ID: 37816353
[TBL] [Abstract][Full Text] [Related]
14. TruNeo: an integrated pipeline improves personalized true tumor neoantigen identification.
Tang Y; Wang Y; Wang J; Li M; Peng L; Wei G; Zhang Y; Li J; Gao Z
BMC Bioinformatics; 2020 Nov; 21(1):532. PubMed ID: 33208106
[TBL] [Abstract][Full Text] [Related]
15. A proteogenomic approach to target neoantigens in solid tumors.
Verma A; Halder A; Marathe S; Purwar R; Srivastava S
Expert Rev Proteomics; 2020; 17(11-12):797-812. PubMed ID: 33491499
[TBL] [Abstract][Full Text] [Related]
16. Engineering neoantigen vaccines to improve cancer personalized immunotherapy.
Liu Z; Lv J; Dang Q; Liu L; Weng S; Wang L; Zhou Z; Kong Y; Li H; Han Y; Han X
Int J Biol Sci; 2022; 18(15):5607-5623. PubMed ID: 36263174
[TBL] [Abstract][Full Text] [Related]
17. Groundwork for AI: Enforcing a benchmark for neoantigen prediction in personalized cancer immunotherapy.
Jaton F
Soc Stud Sci; 2023 Oct; 53(5):787-810. PubMed ID: 37650579
[TBL] [Abstract][Full Text] [Related]
18. pVACview: an interactive visualization tool for efficient neoantigen prioritization and selection.
Xia H; Hoang M; Schmidt E; Kiwala S; McMichael J; Skidmore ZL; Fisk B; Song JJ; Hundal J; Mooney T; Walker JR; Goedegebuure SP; Miller CA; Gillanders WE; Griffith OL; Griffith M
ArXiv; 2024 Jun; ():. PubMed ID: 38947921
[TBL] [Abstract][Full Text] [Related]
19. SIGANEO: Similarity network with GAN enhancement for immunogenic neoepitope prediction.
Ye Y; Shen Y; Wang J; Li D; Zhu Y; Zhao Z; Pan Y; Wang Y; Liu X; Wan J
Comput Struct Biotechnol J; 2023; 21():5538-5543. PubMed ID: 38034402
[TBL] [Abstract][Full Text] [Related]
20. Targeting neoantigens for cancer immunotherapy.
Zhao X; Pan X; Wang Y; Zhang Y
Biomark Res; 2021 Jul; 9(1):61. PubMed ID: 34321091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
